CliffBio
small molecule

SPRAVATO

ESKETAMINE HYDROCHLORIDE

Loss of exclusivityFebruary 2040latest FDA-listed patent expiry
CompanyJanssen Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameSPRAVATO
Active ingredientESKETAMINE HYDROCHLORIDE
StrengthEQ 28MG BASE
Dosage formSPRAY
RouteNASAL
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusRX

Listed patents

PatentExpiresType
11883526February 2040use U-3813
10869844September 2035use U-3036
11173134September 2035use U-3257
11311500September 2035use U-3035
11446260March 2034use U-3446
8785500March 2033use U-4112
9592207March 2027use U-4112

Regulatory exclusivity

CodeExpires
I-959January 2028

More from Janssen Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SPRAVATO patent cliff — loss of exclusivity February 2040 | CliffBio